Ruxolitinib 1.5% Topical Cream for the Treatment of Pediatric Alopecia Areata
April 2024
in “
Journal of Drugs in Dermatology
”
Studysummary In this case report, a severe case of pediatric alopecia areata was treated with topical ruxolitinib, a Janus kinase inhibitor, highlighting the limited but promising evidence for this treatment in children.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on jddonline.com →